76 results about "Compulsive disorders" patented technology

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention relates to an obsessive-compulsive disorder diagnosis and symptom degree evaluation system, and belongs to the technical field of medical instruments. The evaluation system comprises a knowledge base module used for storing evaluation questions and used for responding to an evaluation request of a testee and randomly calling the evaluation questions stored in the knowledge base module, the question and answer evaluation module is used for acquiring face video data and electroencephalogram data of the testee in a detection time period and calling a next round of questions according to each round of voice or character answer information of the testee; the acquisition module is used for acquiring face video data and electroencephalogram data of the testee in the detection time period; and the analysis and evaluation module is used for analyzing the compulsive behavior and the compulsive thinking degree of the detected person in the detection time period. According to the invention, optical flow analysis and 3D face reconstruction sentiment analysis and evaluation are carried out based on face video data, the analysis and evaluation process is more efficient, and the analysis and evaluation result is more accurate; according to the method, multi-modal data such as electroencephalogram signals and 3D reconstruction are combined, and the emotion recognition effect can be further improved.

The invention discloses an obsessive-compulsive disorder diagnosis system based on brain multi-modal indexes, and belongs to the field of mental diseases. The problem of lack of a cross-modal feature fusion mechanism is solved. The system comprises an electroencephalogram signal acquisition unit used for acquiring an EEG signal of a testee under a preset stimulation normal form and executing preprocessing operation; the brain imaging data acquisition unit is used for synchronously acquiring brain structure imaging data and brain function imaging data of the testee; the multi-modal data fusion unit is used for extracting frequency band power spectrum density characteristics and event-related potential amplitude or incubation period characteristics from the EEG signals; performing standardization processing on the EEG features, the sMRI structural features and the fMRI functional features; integrating modal features by adopting a weighted average fusion algorithm; screening fused feature subsets through a recursive feature elimination method; and the diagnosis model unit is used for inputting the fusion feature vector into a trained SVM classification model and outputting an obsessive-compulsive disorder diagnosis result. Used in the medical field.

This invention pertains to a cognitive-coping therapy (CCT) method, system, and application that is a computer-implemented method for implementing AI-based CCT for a patient using natural language processing (NLP) and / or human-machine dialogue with / without an avatar. Based on the cognitive psychology and stress-coping theory, the CCT alleviates the excessive fear of negative event(s) and can be used to address mental disorders / conditions like obsessive-compulsive disorder (OCD), anxiety disorders (e.g., panic disorder, social phobia), and more. The AI system uses the NLP to comprehend the patient's symptoms and provide relevant interventions. Additionally, the system can monitor the patient's progress over time and adapt the interventions accordingly.

The invention relates to a deep learning-based obsessive-compulsive disorder recognition intervention method and intervention system, and the method comprises the steps: carrying out the segmentation training of a collected video image of a target object when the target object appears in a visual field, predicting the obsessive-compulsive disorder correlation degree, and carrying out the segmentation training of the collected video image of the target object when the target object is not in the visual field; multiple physiological index data of obsessive-compulsive disorder persons are collected through the bracelet, a fuzzy neural network is adopted for prediction, obsessive-compulsive disorder relevancy detected under two scenes can achieve data fusion, finally, a target control function is judged, a remote control instruction is sent to the bracelet in time when an obsessive-compulsive disorder behavior occurs, and the obsessive-compulsive disorder behavior is controlled. And meanwhile, the bracelet display screen is used for reminding the user of'relaxing ', so that the obsessive-compulsive disorder person is postponed physically and mentally and jumps out of the obsessive-compulsive disorder mode. Therefore, according to the technical scheme, the obsessive-compulsive disorder behavior of the person is accurately and efficiently predicted, and the obsessive-compulsive disorder behavior is timely intervened and guided in an audio-visual mode on the basis of prediction.

Systems and methods of neurofeedback intervention reduce the negative effects of neurological disorders, including Parkinson's disease, essential tremor, dystonia, epilepsy, dysfunction following stroke, obsessive-compulsive disorder, Tourette syndrome, dementia, complex regional pain syndrome, and the like. Haptic devices, including eccentric-mass actuators and computer-controlled tightening haptic straps provide haptic sensation to a body. The haptic sensations are controlled by a haptic control signal determined by a control program. The control program may determine the haptic control signal from a neurological signal from an EEG, an electrode detecting a signal in a nerve fiber, or an accelerometer. Haptic therapy un-trains and desynchronizes abnormal neuron synchrony, to reduce the negative effects of neurological disorders.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The present invention relates to Compound 1 for the use in the treatment of Major Depressive Disorder, Treatment-resistant Depression, Bipolar Depressive Disorder, Depressive Episodes associated with Bipolar disorders, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, and / or Borderline Personality Disorder, chemical synthesis of Compound 1, polymorphs of Compound 1, and pharmaceutical compositions comprising Compound 1 and / or its polymorphs.

The invention belongs to the technical field of biomedical imaging, and particularly discloses an in-vivo imaging method of an SAPAP3 gene defect disease model, which is characterized in that an effective dose of an S1PR1 receptor targeted radioactive probe is injected into the body of the SAPAP3 gene defect disease model. According to the method, an S1PR1 receptor targeting radioactive probe is utilized, the technical bottleneck that in-vivo and dynamic observation of the S1PR1 receptor cannot be achieved through an existing in-vitro technology is solved, and an indispensable visual tool and a quantitative evaluation means are provided for studying the neurobiological mechanism of related mental diseases such as obsessive-compulsive disorder and accelerating research and development of related drugs.

A pathway planning apparatus includes a processor configured to plan a pathway for implanting an electrode lead into a brain of a patient, wherein the planned pathway satisfies the following condition: if the electrode lead is implanted into the brain of the patient according to the pathway, the electrode lead is capable of simultaneously making contact with an anterior limb of an internal capsule and a nucleus accumbens in one hemisphere of a brain of the patient. The pathway planned by the pathway planning apparatus enables the electrode lead to simultaneously deliver the electrical stimulation to the anterior limb of the internal capsule and the nucleus accumbens such that a combined electrical stimulation therapy is achieved, which has a better effect of treating diseases such as addictive behaviors, depressive disorders, and obsessive-compulsive disorders.

In alternative embodiments, provided are products of manufacture, including devices and integrated systems, and methods, for reducing error-related negativity (ERN) and anxiety, and for treating or ameliorating Anxiety Disorders such as Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD) and obsessive-compulsive disorder (OCD).

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and / or solvate thereof. The invention also relates to the use of the compounds of formula (I) as a medicament, in particular for the prevention or treatment of obsessive-compulsive disorder and related behaviors, including addiction, obsessive-compulsive disorder and dietary disorder, and neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

A modified-release tablet dosage form containing tolcapone is disclosed. The tablet dosage form provides a pulsatile, pH-dependent release profile of tolcapone to both the gastric cavity and the small intestine. Methods for treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's disease, and obsessive-compulsive disorder using the dosage form are provided.

To provide a treatment support device, a treatment support method, and a program capable of facilitating input by a patient and saving time and effort for creating a symptom list and an anxiety hierarchy table in treatment of obsessive-compulsive disease.SOLUTION: The treatment assistance apparatus 1 includes the symptom information acquisition unit 33 that acquires symptom information, which is information about symptoms, from the patient terminal 2 that receives treatment for obsessive-compulsive disease, the anxiety degree information acquisition unit 34 that acquires anxiety degree information, which is information about the relative degree of anxiety of the patient about the symptoms, from the patient terminal 2, and the information acquisition control unit 32 that receives inputs of the symptom information and the anxiety degree information about the symptoms from the patient terminal 2 in parallel.SELECTED DRAWING: Figure 3

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment of anxiety and related conditions, including Generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety disorder, anxious depression, and phobias, the methods comprising administering to the subject a therapeutically effective amount of a compound.

Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

The application relates to application of Lactobacillus murinus in preparation of a drug for treating obsessive-compulsive disorder. The application provides application of Lactobacillus murinus in preparation of a drug for treating obsessive-compulsive disorder, two different OCD mouse models are used to systematically evaluate the intervention effect of Lactobacillus murinus on obsessive-compulsive behavior, and the potential molecular mechanism is preliminarily explored. The results show that the intervention of Lactobacillus murinus can effectively improve the anxiety and obsessive-compulsive behavior of OCD model mice. Further mechanism research finds that the intervention effect may be related to the increase of the activity of excitatory neurons in the medial prefrontal cortex (mPFC) of Lactobacillus murinus.

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt and / or solvate thereof. The present invention also relates to the use of the compound of formula (I) as a drug, in particular for preventing or treating compulsive disorders and related behaviors, including addiction, obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

The invention provides an obsessive-compulsive disorder animal model and a construction method and application thereof, and relates to the technical field of animal models. A construction method of an obsessive-compulsive disorder animal model comprises the following steps: S1, injecting a quantel solution into a rat according to a standard of 0.5 mg / kg, carrying out neck subcutaneous injection twice a week, and continuously injecting for 5 weeks; s2, detecting behavior characteristics of the rats after administration to obtain a basic animal model; and S3, implanting an electrode into the brain of the basic animal model to obtain a target animal model. According to the method, the neurotransmitter activity condition of the corresponding brain region under the disease state can be completely displayed, and an important foundation is laid for exploring the OCD pathogenesis. According to the animal model and the application thereof, the pathophysiological mechanism of OCD and the treatment mechanism of NAc-DBS can be explored from multiple aspects of animal behavioristics, neuroelectrophysiology, histopathology, molecular biology and the like, and a theoretical basis is laid for clarification of OCD pathogenesis and development of new treatment means.

Provided are compositions for use in treating a patient suffering from a mental disorder in particular major depressive disorder, persistent depressive disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Further provided are dosing regimens for treating these disorders.

The invention discloses an obsessive-compulsive disorder data analysis system and method, and relates to the technical field of artificial intelligence, and the system comprises a first collection module which is used for extracting heart rate variability characteristics from pure rPPG signals; the second acquisition module is used for acquiring obsessive-compulsive disorder grade evaluation data of the patient and extracting obsessive-compulsive disorder grade features and obsessive-compulsive disorder category features from the obsessive-compulsive disorder grade evaluation data; the training set construction module is used for constructing a comprehensive obsessive-compulsive disorder feature set; the training module is used for obtaining an optimal obsessive-compulsive disorder analysis model; the recognition module is used for constructing a to-be-detected obsessive-compulsive disorder comprehensive feature set and inputting the to-be-detected obsessive-compulsive disorder comprehensive feature set into the optimal obsessive-compulsive disorder analysis model to obtain an obsessive-compulsive disorder recognition result corresponding to the to-be-detected patient, and the obsessive-compulsive disorder recognition result corresponding to the to-be-detected patient is obtained. The problem that the obsessive-compulsive disorder cannot be accurately and intelligently judged in the prior art is solved.

The invention provides a deep learning-based high-accuracy obsessive-compulsive disorder classification model OCD-AttModel which is used for obsessive-compulsive disorder recognition in electroencephalogram signals, and aims to solve the problems of less study on an obsessive-compulsive disorder classification model based on deep learning, insufficient extraction of transverse sequence features by a deep learning model, low value density of extracted features and the like. According to the model, differences among subjects are fully considered, and robust features with discrimination capability are identified through windowing and one-hot coding of electroencephalogram signals. Extracting the spatial dimension features by using Block1 to generate a plurality of feature matrixes; and then feature processing is carried out on the transverse sequence dimension through Block2. And after each feature extraction module, a feature correction module fusing space Dropout and an optimized self-attention mechanism is inserted, so that features with higher values are screened, and accurate recognition of obsessive-compulsive disorder is realized.

A pharmaceutical composition for treating obsessive-compulsive disorder is provided. The present invention relates to (1) a pharmaceutical composition comprising a dopamine D1 receptor agonist as an effective ingredient for treating obsessive-compulsive disorder, and / or (2) a pharmaceutical composition comprising a dopamine D1 and D2 receptor stimulator, which is administered in combination with a dopamine D2 receptor inhibitor for the purpose of stimulating the dopamine D1 receptor in the striatum, and / or (3) a pharmaceutical composition comprising a dopamine D2 receptor inhibitor, which is administered in combination with a dopamine D1 and D2 receptor stimulator.

This invention provides an apophene derivative, its preparation method, and its application. The general formula of the apophene derivative structure described in this invention is shown below: Among them, R 1 C 1 -C 8 alkoxy or hydrogen, R 2 For hydroxyl or hydrogen; R 3 Selected from C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, C 2 -C 10 alkynyl group, C 2 -C 10 alkenyl, halogen, C 1 -C 8 Halogenated, cyano, nitro, or aryl. The use of the 5-hydroxytryptamine 2A receptor agonist and 5-hydroxytryptamine 2C receptor agonist described in this invention in the preparation of medicaments for the prevention and / or treatment of obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes, and drug addiction.